Coeptis Therapeutics (NASDAQ:COEP) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Coeptis Therapeutics (NASDAQ:COEP) issued its quarterly earnings data on Friday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01, Zacks reports.

Coeptis Therapeutics Price Performance

NASDAQ COEP opened at $0.20 on Monday. The firm’s fifty day simple moving average is $0.27 and its two-hundred day simple moving average is $0.34. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.03. Coeptis Therapeutics has a 12-month low of $0.17 and a 12-month high of $1.38. The firm has a market capitalization of $7.49 million, a P/E ratio of -0.38 and a beta of -0.90.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH lowered shares of Coeptis Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 18th.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.